利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

471 条记录 (耗时 0.029 秒)

    INTEGRATED CELLS
    4.
    发明申请
    INTEGRATED CELLS 审中-公开
    集成的细胞

    公开(公告)号：WO2017137611A1

    公开(公告)日：2017-08-17

    申请号：PCT/EP2017/053084

    申请日：2017-02-10

    申请人： SPIBER TECHNOLOGIES AB

    发明人： HEDHAMMAR, My

    IPC分类号： C12N5/00 ,  C07K14/435

    CPC分类号： C12N5/0068 ,  C07K14/435 ,  C12N2533/50 ,  C12N2533/90

    摘要： A cell scaffold material is manufactured by providing an aqueous solution of a silk protein capable of assembling into a water-insoluble macrostructure. The silk protein is mixed with eukaryotic cells, and the silk protein is assembled into a water-insoluble macrostructure in the presence of the cells, thereby forming a scaffold material for cultivating the cells. The cells can be grown integrated with the scaffold material under conditions suitable for cell culture.

    摘要翻译： 通过提供能够组装成不溶于水的宏观结构的丝蛋白水溶液来制造细胞支架材料。 将丝蛋白与真核细胞混合，并且在细胞存在下将丝蛋白组装成不溶于水的宏观结构，从而形成用于培养细胞的支架材料。 细胞可以在适合细胞培养的条件下与支架材料整合生长。

    TISSUE-ENGINEERED THREE-DIMENSIONAL MODEL FOR TUMOR ANALYSIS
    5.
    发明申请
    TISSUE-ENGINEERED THREE-DIMENSIONAL MODEL FOR TUMOR ANALYSIS 审中-公开
    组织工程三维肿瘤分析模型

    公开(公告)号：WO2017112919A1

    公开(公告)日：2017-06-29

    申请号：PCT/US2016/068478

    申请日：2016-12-23

    申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

    发明人： VUNJAK-NOVAKOVIC, Gordana

    IPC分类号： A61K35/32 ,  C12N5/071 ,  C12M3/00 ,  C12N5/09

    CPC分类号： C12N5/0697 ,  C12N5/0654 ,  C12N5/0655 ,  C12N5/0693 ,  C12N2502/1311 ,  C12N2502/1317 ,  C12N2502/30 ,  C12N2506/115 ,  C12N2506/1353 ,  C12N2533/54 ,  C12N2533/90

    摘要： A tissue engineered three-dimensional model is provided. The three-dimensional includes Ewing's sarcoma (ES) tumor cells; and an engineered human bone scaffold. The engineered human bone scaffold further includes osteoblasts that secrete substance of the human bone, and osteoclasts that absorb bone tissue during growth and healing. The engineered human bone scaffold includes the tissue engineered three dimensional model which recapitulates the osteolytic process. The engineered human bone scaffold is engineered by co-culturing of osteoblasts and osteoclasts. The osteoblast is produced by cell differentiation process from mesenchymal stem cells. The osteoclast is produced by cell differentiation from human monocytes, wherein the human monocytes are isolated from buffy coats.

    摘要翻译： 提供了组织工程化的三维模型。 三维包括尤因肉瘤（ES）肿瘤细胞; 和一个工程人体骨支架。 工程人骨支架还包括分泌人骨的物质的成骨细胞和在生长和愈合过程中吸收骨组织的破骨细胞。 工程人体骨支架包括重组溶骨过程的组织工程三维模型。 工程人骨支架通过共培养成骨细胞和破骨细胞而工程化。 成骨细胞是通过间充质干细胞的细胞分化过程产生的。 破骨细胞由人单核细胞的细胞分化产生，其中人类单核细胞从血沉棕黄层分离。

    METHODS OF DIFFERENTIATING RETINAL CELLS
    7.
    发明申请
    METHODS OF DIFFERENTIATING RETINAL CELLS 审中-公开
    分化视网膜细胞的方法

    公开(公告)号：WO2017091844A1

    公开(公告)日：2017-06-08

    申请号：PCT/AU2016/000390

    申请日：2016-12-05

    申请人： BOND UNIVERSITY LTD

    发明人： IOANNiS, Jason Limnios

    IPC分类号： C12N5/071

    CPC分类号： C12N5/0621 ,  C12N2500/98 ,  C12N2501/385 ,  C12N2501/727 ,  C12N2501/998 ,  C12N2501/999 ,  C12N2506/02 ,  C12N2533/52 ,  C12N2533/90

    摘要： The invention provides a differentiation protocol to generate retinal pigmented epithelial cells (RPECs) for the in vitro differentiation of mammalian pluripotent stem cells to mature, functional retinal pigment epithelial cells (RPEC). A culture system is described that uses defined medium comprising xeno-free optimal combinations of small molecule agonists and antagonists where: (a) pluripotent stem cells are cultured in the absence of feeder cells, serum, or conditioned medium; (b) defined culture conditions is used to obtain an eye-field cell (EFC) population; (c) whereby EFC are subsequently differentiated to RPEC when exposed to culture medium containing small molecule agonists thus producing highly homogenous RPEC; and (d) cultured under optimal conditions until maturation, through stimulation via activin-like signalling through addition of either cyclic AMP or cyclic AMP inducers to produce complete monolayer formation within 21 +7 days. An alternate differentiation procedure also takes EFC intermediates prepared above into photoreceptors.

    摘要翻译： 本发明提供了产生用于将哺乳动物多能干细胞体外分化为成熟的功能性视网膜色素上皮细胞（RPEC）的视网膜色素上皮细胞（RPEC）的分化方案。 描述了使用包含小分子激动剂和拮抗剂的无异源最佳组合的确定培养基的培养系统，其中：（a）在缺乏饲养细胞，血清或条件培养基的情况下培养多能干细胞; （b）确定的培养条件用于获得眼部细胞（EFC）群体; （c）当EFC暴露于含有小分子激动剂的培养基中时，随后分化成RPEC，从而产生高度均一的RPEC; 和（d）在最佳条件下培养直至成熟，通过加入环AMP或环AMP诱导剂经由激活素样信号传导刺激以在21 + 7天内产生完全的单层形成。 另一种分化程序也将EFC中间体制备成光感受器。

    MULTI-LAYER AIRWAY ORGANOIDS AND METHODS OF MAKING AND USING THE SAME
    9.
    发明申请
    MULTI-LAYER AIRWAY ORGANOIDS AND METHODS OF MAKING AND USING THE SAME 审中-公开
    多层气道有机物及其制备和使用方法

    公开(公告)号：WO2017066507A1

    公开(公告)日：2017-04-20

    申请号：PCT/US2016/056947

    申请日：2016-10-14

    申请人： WAKE FOREST UNIVERSITY HEALTH SCIENCES

    发明人： MURPHY, Sean V. ,  ATALA, Anthony

    IPC分类号： C12N5/071 ,  C12N5/00 ,  C12M1/00 ,  C12M3/00

    CPC分类号： C12M21/08 ,  C12M23/16 ,  C12M23/22 ,  C12N5/0688 ,  C12N5/0697 ,  C12N2502/27 ,  C12N2502/28 ,  C12N2533/54 ,  C12N2533/90

    摘要： Provided herein are artificial lung organoids. The artificial lung organoids may include an epithelial cell layer comprising mammalian lung epithelial cells, a stromal cell layer comprising mammalian lung fibroblast cells and an endothelial cell layer comprising mammalian endothelial cells. The artificial lung organoids may optionally include a porous membrane between said epithelial cell layer and said stromal cell layer and/or between said stromal cell layer and said endothelial lung cell layer.

    摘要翻译： 本文提供人造肺器官组织。 人造肺类器官可包括含有哺乳动物肺上皮细胞的上皮细胞层，含有哺乳动物肺成纤维细胞的基质细胞层和含有哺乳动物内皮细胞的内皮细胞层。 人造肺类器官可以任选地包括在所述上皮细胞层和所述基质细胞层之间和/或在所述基质细胞层和所述内皮肺细胞层之间的多孔膜。

    USE OF DERMATOPONTIN FOR MAINTAINING HEMATOPOIETIC STEM AND/OR PROGENITOR CELLS IN CULTURE
    10.
    发明申请
    USE OF DERMATOPONTIN FOR MAINTAINING HEMATOPOIETIC STEM AND/OR PROGENITOR CELLS IN CULTURE 审中-公开
    用于维持文化中HEMATOPOIETIC STEM和/或PROGENITOR细胞的DERMATOPONTIN的使用

    公开(公告)号：WO2017021543A1

    公开(公告)日：2017-02-09

    申请号：PCT/EP2016/068790

    申请日：2016-08-05

    申请人： HELMHOLTZ ZENTRUM MÜNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) ,  EIDGENÖSSISCHE TECHNISCHE HOCHSCHULE ZÜRICH

    发明人： KOKKALIARIS, Konstantinos ,  SCHROEDER, Timm

    IPC分类号： C12N5/0789 ,  A61K35/12

    CPC分类号： C12N5/0647 ,  A61K35/12 ,  C12N2500/90 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/998 ,  C12N2502/13 ,  C12N2533/54 ,  C12N2533/90

    摘要： The present invention relates to the use of dermatopontin (DPT) or a functional fragment thereof for the maintenance of hematopoietic stem and/or progenitor cells in culture. The present invention further relates to a method for maintaining hematopoietic stem and/or progenitor cells in culture, the method comprising culturing the hematopoietic stem and/or progenitor cells in the presence of dermatopontin (DPT) or a functional fragment thereof. Furthermore, the present invention relates to a cell culture medium for the maintenance of hematopoietic stem and/or progenitor cells, wherein the cell culture medium comprises a medium and dermatopontin (DPT) or a functional fragment thereof and further optionally comprises serum/serum replacement, (a) reducing agent(s), and/or (an) antibiotic(s) as well as a kit comprising dermatopontin (DPT) or a functional fragment thereof and at least one of: (a) (a) cell culture medium; (b) one or more cytokines; (c) serum/serum replacement; (d) (a) reducing agent(s), and/or (e) (an) antibiotic(s).

    摘要翻译： 本发明涉及皮肤素（DPT）或其功能片段用于维持培养中造血干细胞和/或祖细胞的用途。 本发明还涉及用于在培养物中维持造血干细胞和/或祖细胞的方法，所述方法包括在皮肤素（DPT）或其功能片段的存在下培养造血干细胞和/或祖细胞。 此外，本发明涉及用于维持造血干细胞和/或祖细胞的细胞培养基，其中细胞培养基包含培养基和皮肤粘蛋白（DPT）或其功能片段，并且还任选地包含血清/血清替代物， （a）还原剂和/或（一种）抗生素以及包含皮肤素（DPT）或其功能性片段的试剂盒和至少一种：（a）（a）细胞培养基; （b）一种或多种细胞因子; （c）血清/血清替代物; （d）（a）还原剂和/或（e）（a）抗生素。